LINATAB D 5/10 (Linagliptin 5 mg + Dapagliflozin 10 mg Tablets)

Description

DESCRIPTION:
Linatab D 5/10 is a fixed-dose combination of Linagliptin 5 mg and Dapagliflozin 10 mg, two oral antidiabetic agents used in the management of Type 2 Diabetes Mellitus. It is indicated for adult patients whose blood glucose levels are inadequately controlled by diet, exercise, and monotherapy with either Linagliptin or Dapagliflozin.

Type 2 diabetes mellitus is a chronic, progressive condition characterized by insulin resistance and impaired insulin secretion, leading to persistent hyperglycaemia. Effective glycaemic control is essential to prevent or delay diabetes-related complications such as neuropathy, nephropathy, retinopathy, and cardiovascular disease.

Linatab D 5/10 combines two agents with complementary mechanisms of action:

• Linagliptin, a Dipeptidyl Peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones (GLP-1 and GIP), which enhance insulin secretion and suppress glucagon release in a glucose-dependent manner.
• Dapagliflozin, a Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor, reduces blood glucose by promoting urinary glucose excretion through inhibition of renal glucose reabsorption.

Together, these agents improve glycaemic control through both insulin-dependent and insulin-independent pathways, providing better fasting and postprandial blood glucose management with additional benefits such as weight reduction and blood pressure improvement.

USES:

• Management of Type 2 Diabetes Mellitus in adults
• As an adjunct to diet and exercise for improved glycaemic control
• May be used as combination therapy when monotherapy with either component is insufficient

MEDICINAL BENEFITS:

• Dual mechanism for optimal glycaemic control
• Promotes mild weight loss and blood pressure reduction
• Low risk of hypoglycaemia when used as directed
• Provides cardiovascular and renal protection benefits associated with Dapagliflozin
• Improves beta-cell function and insulin sensitivity

DOSAGE & ADMINISTRATION:
Dosage should be individualized based on patient needs and clinical response. The usual recommended dose is one tablet once daily, taken with or without food. Swallow the tablet whole with a glass of water. Do not crush or chew. Continue therapy as directed by your physician.

STORAGE:
Store in a cool, dry place below 25°C. Protect from moisture and direct sunlight. Keep out of reach of children.

CONTRAINDICATIONS:

• Hypersensitivity to Linagliptin, Dapagliflozin, or any excipients
• Severe renal impairment (eGFR < 30 mL/min/1.73 m²) or patients on dialysis
• Type 1 diabetes mellitus or diabetic ketoacidosis
• History of serious hypersensitivity reactions (e.g., angioedema) to DPP-4 inhibitors

WARNINGS & PRECAUTIONS:

• Use with cautions
• Maintain adequate hydration to prevent dehydration and hypotension
• Monitor for signs of urinary tract infections or genital mycotic infections
• Temporarily discontinue before surgery or during acute illness to avoid ketoacidosis risk
• Avoid excessive alcohol intake during therapy
• Use in pregnancy or lactation only under medical supervision

SIDE EFFECTS:
Common side effects may include increased urination, mild urinary tract infection, genital fungal infection, headache, nasopharyngitis, or mild hypoglycaemia (especially if used with other antidiabetic agents). Most effects are transient and mild. Consult your doctor if any side effects persist or worsen.

DISCLAIMER:
Linatab D 5/10 should be used only under the supervision of a qualified healthcare professional. Dosage and duration must be based on medical advice, patient response, and blood glucose monitoring.